2-[2-[3,4-Bis(2-hydroxyethoxy)oxolan-2-yl]-2-(2-hydroxyethoxy)ethoxy]ethyl octadec-9-enoate | 1030828-02-4

• 物质功能分类: 表面活性剂 - 非离子表面活性剂 - 多元醇酯型
• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: 2-[2-[3,4-Bis(2-hydroxyethoxy)oxolan-2-yl]-2-(2-hydroxyethoxy)ethoxy]ethyl octadec-9-enoate
• CAS: 1030828-02-4
• 化学式: C₃₂H₆₀O₁₀
• 分子量: 604.8
• InChiKey: HDTIFOGXOGLRCB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.8
• 重原子数：
  42
• 可旋转键数：
  31
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.91
• 拓扑面积：
  133
• 氢给体数：
  3
• 氢受体数：
  10

ADMET

毒理性

• 相互作用

聚山梨酯80对甲氨蝶呤（MTX）的生物利用度和分布的影响在口服给药后在NMRI和Porton小鼠中进行了研究。在这两种品系的小鼠中，通过这种非离子表面活性剂，各种器官中的MTX浓度增加了。

Effect of polysorbate 80 on the bioavailability and distribution of methotrexate (MTX) was studied in NMRI and Porton mice following oral administration. In these two strains of mice concentrations of MTX were increased in various organs by this nonionic surfactant.

来源:Hazardous Substances Data Bank (HSDB)

毒理性

• 相互作用

Tween 80增强了道诺霉素对Ehrlich腹水瘤大鼠和离体肿瘤细胞的抗肿瘤效果。在亚细胞水平上，Tween 80增加了道诺霉素与细胞核和线粒体的结合。

Tween 80 potentiated the antitumor effects of daunomycin both in rats with Ehrlich ascites tumor and in isolated tumor cells. At the subcellular level, Tween 80 increased binding of daunomycin to the nucleus and mitochondria.

来源:Hazardous Substances Data Bank (HSDB)

毒理性

• 相互作用

在中国仓鼠细胞系对放线菌素D和道诺霉素产生耐药性的培养中，使用非离子表面活性剂Tween 80处理增强了这两种抗生素在生长研究中的效果并提高了摄取。

In cultures of Chinese hamster cell lines resistant to actinomycin D and daunomycin, treatment with the nonionic surfactant Tween 80 potentiated the effects of the 2 antibiotics in growth studies and enhanced uptake.

来源:Hazardous Substances Data Bank (HSDB)

毒理性

• 相互作用

多柔比星在10%吐温80水溶液中，通过静脉注射给携带肉瘤的小鼠，比单独给予多柔比星具有更高的抗肿瘤活性，并且在小鼠的脾脏、肺和肾脏中产生更高的多柔比星水平。

Adriamycin in a 10% Tween 80 aqueous solution injected iv into sarcoma-bearing mice had higher antitumor activity and produced higher adriamycin levels in the spleen, lung, and kidney than did adriamycin given alone.

来源:Hazardous Substances Data Bank (HSDB)

毒理性

• 解毒与急救

/SRP:/ 立即急救：确保已经进行了充分的中和。如果患者停止呼吸，请开始人工呼吸，最好使用需求阀复苏器、球囊阀面罩设备或口袋面罩，按训练操作。如有必要，执行心肺复苏。立即用缓慢流动的水冲洗受污染的眼睛。不要催吐。如果患者呕吐，让患者向前倾或将其置于左侧（如果可能的话，头部向下）以保持呼吸道畅通，防止吸入。保持患者安静，维持正常体温。寻求医疗救助。 /毒物A和B/

/SRP:/ Immediate first aid: Ensure that adequate decontamination has been carried out. If patient is not breathing, start artificial respiration, preferably with a demand valve resuscitator, bag-valve-mask device, or pocket mask, as trained. Perform CPR if necessary. Immediately flush contaminated eyes with gently flowing water. Do not induce vomiting. If vomiting occurs, lean patient forward or place on the left side (head-down position, if possible) to maintain an open airway and prevent aspiration. Keep patient quiet and maintain normal body temperature. Obtain medical attention. /Poisons A and B/

来源:Hazardous Substances Data Bank (HSDB)

文献信息

• APPARATUS AND METHODS FOR HYGIENE TESTING A MEDICAL DEVICE
  申请人：Novaflux, Inc.

  公开号：EP3504531A1

  公开（公告）日：2019-07-03
• IMMEDIATE RELEASE CLINDAMYCIN DELIVERY COMPOSITION AND FORMULATION
  申请人：Iono Pharma, LLC

  公开号：US20180256746A1

  公开（公告）日：2018-09-13

  This invention relates to a pharmaceutical composition made of a clindamycin salt complexed with strongly acidic non-spherical resin particles, wherein predominantly all of the resin particles are less than 75 microns in diameter, to form clindamycin-resin complex, wherein in the clindamycin-resin complex provides for immediate release of the clindamycin in a target environment and at least one non-ionic excipient. In one embodiment, the inventive subject matter is an oral liquid pharmaceutical formulation made of a complex of clindamycin hydrochloride, a fractionated resin and excipients to stabilize the complex. The pharmaceutical formulation remains stable in deionized water until the dosage form reaches an ion-rich environment (stomach or intestine), there which the active ingredient clindamycin hydrochloride is released.
• [EN] APPARATUS AND METHODS FOR HYGIENE TESTING A MEDICAL DEVICE<br/>[FR] APPAREILS ET PROCÉDÉS DESTINÉS À TESTER L'HYGIÈNE D'UN DISPOSITIF MÉDICAL
  申请人：NOVAFLUX INC

  公开号：WO2018039443A1

  公开（公告）日：2018-03-01

  Provided among other things is a sampling system for determining an amount or type of contamination a narrow, elongated passageway in a medical device, said sampling system comprising: (a) a fluid supply system that supplies to said passageway a sampling liquid for flowing through said passageway and a gas for flowing through said passageway; and (b) a receiving container that receives liquid from said passageway, wherein said sampling liquid is sterile, wherein said sampling liquid is configured to allow recovery of viable pathogens from the passageway, and wherein said sampling liquid comprises an amount and selection of surfactant effective to enhance the dislodgement of Enterococcus faecalis and Pseudomonas aeruginosa bacteria from the narrow passageways.

表征谱图